Liberty Remedy for Life Sciences™: specialist cover for a complex sector

Liberty has been selectively writing life sciences risk since 2018, gradually building our capability in defined segments. This considered build-up allowed us to build a deep understanding of the industry before broadening our offering and bringing this product to market.  

Responding to market feedback  

Liberty Remedy was developed in consultation with brokers, risk managers and life sciences companies. Market feedback was clear; policy wordings were too long, too complicated and difficult to navigate. We responded by simplifying policy wording, removing exclusions (where we could), and providing broader, clearer cover. 

Building specialist capability  

The technical complexity of the life sciences sector creates a high barrier to entry. Liberty's risk engineering capability sets it apart in the region. With risk engineers in China, Hong Kong, Singapore and Australia we help assess operations on the ground. Those insights are closely connected to underwriting and claims, so clients benefit from a more joined-up approach. Not only does this help to reduce unnecessary exclusions, but it also means we can provide coverage that’s easier to understand and more useful in practice. 

Liberty also spent time building its claims capability with the technical expertise that the sector demands. For life sciences companies, claims can be financially significant, technically complex and time sensitive. At Liberty, our claims support is part of the wider risk management relationship, not simply a back-end service. There’s a genuine partnership between our technical risk engineers, our claims specialists and our underwriters. 

The Liberty advantage 

Liberty Remedy is intended to work for Asia Pacific based insureds operating internationally, while still reflecting local conditions and expectations. With access to Liberty’s international network, and with support from locally available claims and risk engineering experts, Liberty Remedy is designed to grow as businesses grow. Liberty can support companies at the start of their journey and can continue to provide protection as they scale into new markets and new stages of development.

Life sciences sector expanding rapidly  

The life sciences sector across Asia Pacific is expanding rapidly. Industry research suggests the broader Asia Pacific life sciences market could triple in size in the decade to 2034, while the Asia Pacific biopharmaceutical market alone is forecast to more than double over the coming years. This growth reflects strong demand for advanced therapies, biologics, diagnostics and medtech solutions, and is supported by government incentives, cross-border supply chains, digital health adoption and a rising role for Asia as a global hub for biopharma innovation and development.